99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Rheumatoid Arthritis
Interventions
DRUG

99mTc-3PRGD2

"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."

Trial Locations (1)

350005

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER

NCT02723760 - 99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients | Biotech Hunter | Biotech Hunter